Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
42
IMTX Quote, Financials, Valuation and Earnings
Last price:
$10.23
Seasonality move
:
-10%
Day range:
$10.22 - $10.50
52-week range:
$3.30 - $12.41
Dividend yield:
0%
P/E ratio:
42.21x
P/S ratio:
13.85x
P/B ratio:
2.57x
Volume:
151K
Avg. volume:
620.4K
1-year change:
46.06%
Market cap:
$1.3B
Revenue:
$168.6M
EPS (TTM):
-$1.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IMTX
Immatics NV
|
$12.5M | -$0.45 | -81.87% | -704.25% | $18.75 |
|
BNTX
BioNTech SE
|
$1.2B | $0.12 | -24.04% | -86.85% | $138.33 |
|
CVAC
CureVac NV
|
$25.1M | -$0.08 | 0.04% | -32.36% | $5.31 |
|
EVO
Evotec SE
|
$219.8M | -$0.01 | 17.8% | -75.1% | $5.4436 |
|
IFRX
InflaRx NV
|
$34.6K | -$0.14 | -74.55% | -16.09% | $11.24 |
|
NNNN
Anbio Biotechnology
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IMTX
Immatics NV
|
$10.37 | $18.75 | $1.3B | 42.21x | $0.00 | 0% | 13.85x |
|
BNTX
BioNTech SE
|
$95.03 | $138.33 | $22.9B | 191.55x | $0.00 | 0% | 6.46x |
|
CVAC
CureVac NV
|
$4.31 | $5.31 | $970.5M | 6.03x | $0.00 | 0% | 11.97x |
|
EVO
Evotec SE
|
$3.1300 | $5.4436 | $1.1B | -- | $0.00 | 0% | 1.34x |
|
IFRX
InflaRx NV
|
$1.14 | $11.24 | $77.2M | -- | $0.00 | 0% | 352.24x |
|
NNNN
Anbio Biotechnology
|
$35.84 | -- | $1.6B | -- | $0.00 | 0% | 171.25x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IMTX
Immatics NV
|
3.78% | 2.023 | 1.86% | 6.97x |
|
BNTX
BioNTech SE
|
1.31% | 1.267 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 1.835 | 3.39% | 1.84x |
|
EVO
Evotec SE
|
37.72% | 1.505 | 44.12% | 1.05x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
NNNN
Anbio Biotechnology
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
EVO
Evotec SE
|
-$72.4K | -$59.7M | -11.62% | -17.7% | -31.17% | -$101.3M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
NNNN
Anbio Biotechnology
|
-- | -- | -- | -- | -- | -- |
Immatics NV vs. Competitors
-
Which has Higher Returns IMTX or BNTX?
BioNTech SE has a net margin of -974.45% compared to Immatics NV's net margin of -1.89%. Immatics NV's return on equity of -25.21% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital IMTXImmatics NV-- -$0.49 $508.8M BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About IMTX or BNTX?
Immatics NV has a consensus price target of $18.75, signalling upside risk potential of 80.81%. On the other hand BioNTech SE has an analysts' consensus of $138.33 which suggests that it could grow by 45.57%. Given that Immatics NV has higher upside potential than BioNTech SE, analysts believe Immatics NV is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings IMTXImmatics NV9 0 0 BNTXBioNTech SE14 5 0 -
Is IMTX or BNTX More Risky?
Immatics NV has a beta of 1.361, which suggesting that the stock is 36.134% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.
-
Which is a Better Dividend Stock IMTX or BNTX?
Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMTX or BNTX?
Immatics NV quarterly revenues are $6.1M, which are smaller than BioNTech SE quarterly revenues of $1.8B. Immatics NV's net income of -$59.1M is lower than BioNTech SE's net income of -$33.5M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 13.85x versus 6.46x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMTXImmatics NV13.85x 42.21x $6.1M -$59.1M BNTXBioNTech SE6.46x 191.55x $1.8B -$33.5M
-
Which has Higher Returns IMTX or CVAC?
CureVac NV has a net margin of -974.45% compared to Immatics NV's net margin of -5832.47%. Immatics NV's return on equity of -25.21% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital IMTXImmatics NV-- -$0.49 $508.8M CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About IMTX or CVAC?
Immatics NV has a consensus price target of $18.75, signalling upside risk potential of 80.81%. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 23.51%. Given that Immatics NV has higher upside potential than CureVac NV, analysts believe Immatics NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings IMTXImmatics NV9 0 0 CVACCureVac NV1 3 0 -
Is IMTX or CVAC More Risky?
Immatics NV has a beta of 1.361, which suggesting that the stock is 36.134% more volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.
-
Which is a Better Dividend Stock IMTX or CVAC?
Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMTX or CVAC?
Immatics NV quarterly revenues are $6.1M, which are smaller than CureVac NV quarterly revenues of $63.3M. Immatics NV's net income of -$59.1M is lower than CureVac NV's net income of $319.3M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while CureVac NV's PE ratio is 6.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 13.85x versus 11.97x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMTXImmatics NV13.85x 42.21x $6.1M -$59.1M CVACCureVac NV11.97x 6.03x $63.3M $319.3M
-
Which has Higher Returns IMTX or EVO?
Evotec SE has a net margin of -974.45% compared to Immatics NV's net margin of -26.29%. Immatics NV's return on equity of -25.21% beat Evotec SE's return on equity of -17.7%.
Company Gross Margin Earnings Per Share Invested Capital IMTXImmatics NV-- -$0.49 $508.8M EVOEvotec SE-0.04% -$0.14 $1.5B -
What do Analysts Say About IMTX or EVO?
Immatics NV has a consensus price target of $18.75, signalling upside risk potential of 80.81%. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 74.58%. Given that Immatics NV has higher upside potential than Evotec SE, analysts believe Immatics NV is more attractive than Evotec SE.
Company Buy Ratings Hold Ratings Sell Ratings IMTXImmatics NV9 0 0 EVOEvotec SE1 0 0 -
Is IMTX or EVO More Risky?
Immatics NV has a beta of 1.361, which suggesting that the stock is 36.134% more volatile than S&P 500. In comparison Evotec SE has a beta of 1.821, suggesting its more volatile than the S&P 500 by 82.079%.
-
Which is a Better Dividend Stock IMTX or EVO?
Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMTX or EVO?
Immatics NV quarterly revenues are $6.1M, which are smaller than Evotec SE quarterly revenues of $191.5M. Immatics NV's net income of -$59.1M is lower than Evotec SE's net income of -$50.3M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 13.85x versus 1.34x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMTXImmatics NV13.85x 42.21x $6.1M -$59.1M EVOEvotec SE1.34x -- $191.5M -$50.3M
-
Which has Higher Returns IMTX or IFRX?
InflaRx NV has a net margin of -974.45% compared to Immatics NV's net margin of -51538.49%. Immatics NV's return on equity of -25.21% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital IMTXImmatics NV-- -$0.49 $508.8M IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About IMTX or IFRX?
Immatics NV has a consensus price target of $18.75, signalling upside risk potential of 80.81%. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 886.3%. Given that InflaRx NV has higher upside potential than Immatics NV, analysts believe InflaRx NV is more attractive than Immatics NV.
Company Buy Ratings Hold Ratings Sell Ratings IMTXImmatics NV9 0 0 IFRXInflaRx NV5 2 0 -
Is IMTX or IFRX More Risky?
Immatics NV has a beta of 1.361, which suggesting that the stock is 36.134% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock IMTX or IFRX?
Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMTX or IFRX?
Immatics NV quarterly revenues are $6.1M, which are larger than InflaRx NV quarterly revenues of $27.8K. Immatics NV's net income of -$59.1M is lower than InflaRx NV's net income of -$14.3M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 13.85x versus 352.24x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMTXImmatics NV13.85x 42.21x $6.1M -$59.1M IFRXInflaRx NV352.24x -- $27.8K -$14.3M
-
Which has Higher Returns IMTX or NNNN?
Anbio Biotechnology has a net margin of -974.45% compared to Immatics NV's net margin of --. Immatics NV's return on equity of -25.21% beat Anbio Biotechnology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IMTXImmatics NV-- -$0.49 $508.8M NNNNAnbio Biotechnology-- -- -- -
What do Analysts Say About IMTX or NNNN?
Immatics NV has a consensus price target of $18.75, signalling upside risk potential of 80.81%. On the other hand Anbio Biotechnology has an analysts' consensus of -- which suggests that it could fall by --. Given that Immatics NV has higher upside potential than Anbio Biotechnology, analysts believe Immatics NV is more attractive than Anbio Biotechnology.
Company Buy Ratings Hold Ratings Sell Ratings IMTXImmatics NV9 0 0 NNNNAnbio Biotechnology0 0 0 -
Is IMTX or NNNN More Risky?
Immatics NV has a beta of 1.361, which suggesting that the stock is 36.134% more volatile than S&P 500. In comparison Anbio Biotechnology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock IMTX or NNNN?
Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anbio Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. Anbio Biotechnology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMTX or NNNN?
Immatics NV quarterly revenues are $6.1M, which are larger than Anbio Biotechnology quarterly revenues of --. Immatics NV's net income of -$59.1M is higher than Anbio Biotechnology's net income of --. Notably, Immatics NV's price-to-earnings ratio is 42.21x while Anbio Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 13.85x versus 171.25x for Anbio Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMTXImmatics NV13.85x 42.21x $6.1M -$59.1M NNNNAnbio Biotechnology171.25x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
GLTO alert for Dec 26
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Sell
27
CDNAF alert for Dec 26
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
